CARES

Cabotegravir And Rilpivirine: Efficacy and Safety Study

Follow up update

Screening and Enrolment overview

Site

Enrolment Target

Total Screened

Total

Randomized

Date of first Randomization

Date of last Randomization

Total

512

1039

512

15th/SEP/2021

31st/AUG/2022

Uganda

101

68

211

108*

22nd/SEP/2021

22nd/AUG/2022

102

67

116

69

15th/SEP/2021

24th/NOV/2021

103

67

106

67

24th/SEP/2021

21st/DEC/2021

Kenya

201

40

57

40

01st/MAR/2022

27th/MAY/2022

202

60

123

62*

22nd/MAR/2022

29th/AUG/2022

203

60

114

60

29th/MAR/2022

07th/JUN/2022

South Africa

301

75

157

97*

11th/NOV/2021

31st/AUG/2022

302

75

155

9

28th/FEB/2022

15th/JUN/2022

Updates on participant follow up Through 31st May 2023

The study has maintained a high follow-up rate of 99.4% (509/512). There have been only two withdrawals and one death that was confirmed as unrelated to the study treatment. The last follow-up visits are months 21 and 22 with a 15%% and 4% completion rate.

Snapshot Of Follow-Up Through Month 22